PMH28 Using Cost-Effectiveness Analysis to Define the Optimal Group of Patients to Benefit From Risperidone Long-Acting Injectable
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.818
https://www.valueinhealthjournal.com/article/S1098-3015(12)02531-4/fulltext
Title :
PMH28 Using Cost-Effectiveness Analysis to Define the Optimal Group of Patients to Benefit From Risperidone Long-Acting Injectable
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02531-4&doi=10.1016/j.jval.2012.08.818
First page :
A338
Section Title :
Mental Health
Open access? :
No
Section Order :
328